Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Test Phase IV, Multicenter, Open, Aiming to test the difference in efficacy of Natalizumab, Versus Fingolimod the 2 drugs Having A AMM for Treatment of Multiple Sclerosis

Next Previous
Trial Profile

Test Phase IV, Multicenter, Open, Aiming to test the difference in efficacy of Natalizumab, Versus Fingolimod the 2 drugs Having A AMM for Treatment of Multiple Sclerosis

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fingolimod (Primary) ; Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms BEST-MS

    • Most Recent Events

    • 30 Oct 2019 This trial has been completed in France, according to European Clinical Trials Database. (2019-01-23)
    • 27 Apr 2018 Results (n=224) assessing efficacy and tolerability of natalizumab with fingolimod as second-line treatment in patients with multiple sclerosis, were presented at the 70th Annual Meeting of the American Academy of Neurology.
    • 21 Feb 2017 Planned End Date changed from 1 Oct 2016 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top